pocketful logo
Aarti Drugs Ltd logo

Aarti Drugs Ltd

NSE: AARTIDRUGS BSE: 524348

₹367

(-0.65%)

Wed, 11 Mar 2026, 01:55 am

mtf coin illustrationMTF 5x

Aarti Drugs Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    3227.31

  • Net Profit

    168.10

  • P/B

    2.27

  • Sector P/E

    32.36

  • P/E

    18.45

  • EV/EBITDA

    12.10

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    20.20

  • ROCE (Industry)

    20.50

  • RONW (Industry)

    17.60

  • ROE

    12.68

  • ROCE

    13.07

  • Debt/Equity

    0.44

  • EPS (TTM)

    22.20

  • Dividend Yield

    0.28

  • Book Value

    160.87

  • Interest Cover

    6.42

Analysis

all

thumbs up icon

Pros

  • Dividends after 3 years are expected to be thoroughly covered by earnings (10.2x coverage).
  • Aarti Drugs's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Aarti Drugs's earnings are expected to exceed the low risk growth rate next year.
  • Aarti Drugs is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
  • Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
thumbs up icon

Cons

  • Aarti Drugs is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
  • No need to calculate the sustainability of Aarti Drugs's dividends as it is not paying a notable one for India.
  • Aarti Drugs is not paying a notable dividend for India, therefore no need to check if the payments are stable.
  • Aarti Drugs's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Aarti Drugs's dividend is below the markets top 25% of dividend payers in India (3.08%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters55.0354.7255.2255.4855.38
FII2.152.692.262.252.28
DII10.129.909.949.708.77
Public32.7032.6932.5832.5733.57
Government00000

Read More

Technical Analysis

RSI

33.65

MACD

-7.29

50 DMA

379.90

200 DMA

451.05

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic513.63447.73407.37381.83341.47315.93250.03
Fibonacci447.73422.56407.01381.83356.66341.11315.93
Camarilla385.12379.08373.04381.83360.96354.92348.88

Pivots Level: Classic

R3

+131.80

513.63

R2

+65.90

447.73

R1

+25.53

407.37

381.83
381.83
Pivot Point
LTP: 353.45

S1

-40.37

341.47

S2

-65.90

315.93

S3

-131.80

250.03

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    360.00

  • 20-EMA

    365.74

  • 30-EMA

    370.58

  • 50-EMA

    381.03

  • 100-EMA

    404.36

  • 200-EMA

    426.50

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
03 Feb 2026dividend₹2.00 Dividend /Share09 Feb 2026
03 Feb 2026board-meetingsAccounts, Quarterly Results, Interim Dividend
09 Jan 2026dividendInterim Dividend - Rs. - 209 Feb 2026
07 Nov 2025board-meetingsQuarterly Results
01 Sept 2025agm
29 Jan 2025dividend₹1.00 Dividend /Share04 Feb 2025
04 Jan 2025dividendInterim Dividend - Rs. - 104 Feb 2025
02 Sept 2024agm
26 Aug 2024buyback
05 Aug 2024buybackBuy Back of Shares05 Sept 2024

Read More

Peer Comparison

Aarti Drugs Ltd logo

Aarti Drugs Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Aarti Drugs Ltd About

Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1984

Headquarters

CEO

Chandrakant V. Gogri

Employees

Contact

Website icon

Website

http://www.aartidrugs.com

Email icon

Email

investorrelations@aartidrugs.com

Phone icon

Phone

91-22-24072249

Location icon

Location

Plot No N-198 MIDC Tarapur, Pamtembhi Village Palghar Tal, Thane, Maharashtra, 401506

Read More

Aarti Drugs Ltd Company History

YearHistory
2015
  • Aarti Drugs Ltd will participate at 'Centrum Pharma Day' Investor Conference
  • The Company has allotted the Bonus Shares to its shareholders in the Ratio of 1:1
2020
  • The Company has issued Bonus Shares in the Ratio of 3:1
2023
  • Aarti Drugs Limited won Pharmexcil Outstanding Exports Awards 2021-22
2024
  • The Company Initiating Commercial Production of Dermatology Product at New Facility in Tarapur, Maharashtra
2025
  • Aarti Drugs Limited has informed the Exchange about Commencement of commercial production/operation.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPBuy803477393.107 May 2025
GRAVITON RESEARCH CAPITAL LLPSell803687393.6207 May 2025
MIRIK RAJENDRA GOGRISell468378485.528 May 2024
BLEND FUND 2Buy511571484.9728 May 2024
GRAVITON RESEARCH CAPITAL LLPBuy480077554.1718 Oct 2023
GRAVITON RESEARCH CAPITAL LLPSell480077554.718 Oct 2023
GRAVITON RESEARCH CAPITAL LLPSell933060628.425 Jul 2023
GRAVITON RESEARCH CAPITAL LLPBuy933060627.8925 Jul 2023
GRAVITON RESEARCH CAPITAL LLPSell643754576.4624 Jul 2023
NK SECURITIES RESEARCH PRIVATE LIMITEDSell553535588.5924 Jul 2023

Read More

Aarti Drugs Ltd News

Aarti Drugs Invests ₹10 Crore in Subsidiary

Aarti Drugs Limited approves ₹10 crore investment in wholly owned subsidiary Pinnacle Life Science through rights issue subscription for expansion and capex funding.

07 Mar 2026

co actions results

Aarti Drugs Forms New Chilean Subsidiary

Aarti Drugs Limited announces incorporation of step-down subsidiary Tripharma Chile SpA through its existing subsidiary Pinnacle Chile SpA for pharmaceutical marketing operations in Chile.

02 Mar 2026

co actions results

Aarti Drugs Declares ₹2 Interim Dividend Per Share

Aarti Drugs announces interim dividend of ₹2 per share for shareholders, demonstrating the company's commitment to returning value to investors through regular dividend distributions.

03 Feb 2026

co actions results

Aarti Drugs Q3 Net Profit Rises 9.7% to ₹406M

Aarti Drugs reports consolidated net profit of ₹406 million in Q3, up from ₹370 million year-on-year. Revenue increased to ₹6 billion from ₹5.57 billion in the same period last year.

03 Feb 2026

co actions results

Aarti Drugs Gets CRISIL Rating Reaffirmation

CRISIL Limited reaffirmed Aarti Drugs' credit ratings with AA-/Stable for long-term and A1+ for short-term facilities totaling Rs. 1,768 crores across multiple banking partners.

29 Jan 2026

stocks

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800